NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

You have to look ar vector gene therapies/companies separately from the gene editing companies. There are several of players in the allogenic CAR-T (thanks to jondoeuk for the education) race and collectively they are adding up to quite a bit of patient experience. They are gene editers and are doing in vivo and ex vivo transfer for conditions like sickle cell and for Allogenic CART, as well as advanced Turbo or Stealth cells which are further edited to reduce NK response.

Vector gene therapy carries quite a bit of added potential risk in my mind. My understanding is that vector gene therapy implants code that just keeps on churning. This can lead to bad effects in terms of potential malignancy or pathological pathways. Some deficiencies when over-expressed create unknown “toxicities”, or even known diseases.

Editing is intended to restore natural expression to normalize output.